Monoamine neurotransmitter pathway components

The monoamine neurotransmitter pathway components comprise a complex network of proteins involved in the life cycle of monoamine signaling molecules, including dopamine, serotonin, and norepinephrine (StatPearls, 2023). This system includes biosynthetic enzymes such as tyrosine hydroxylase, packaging transporters like VMAT2, plasma membrane reuptake transporters such as SERT, DAT, and NET, and various G protein-coupled receptors (Nature Reviews Drug Discovery, 2022). These components are essential for maintaining homeostasis in mood, cognition, and motor functions (NIH, 2021). Dysregulation of monoamine levels or receptor sensitivity is a hallmark of many neuropsychiatric conditions, such as major depressive disorder and schizophrenia (PubMed, 2020). Pharmacological intervention often focuses on modulating these components to restore balanced neurotransmission, making them some of the most heavily researched and utilized therapeutic targets in medicine (StatPearls, 2023).

Other names

Monoaminergic systemMonoamine signaling pathwayMonoamine neurotransmission system

Mechanisms include the inhibition of plasma membrane reuptake transporters (e.g., SERT, DAT, NET) to increase synaptic neurotransmitter residence time, the inhibition of intracellular degradative enzymes (e.g., MAO, COMT) to increase overall neurotransmitter availability, and the direct modulation (agonism or antagonism) of post-synaptic and pre-synaptic G protein-coupled receptors to alter downstream signaling cascades (StatPearls, 2023; NIH, 2022).